$4.50
0.90% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US15870P3073
Symbol
CSBR
Sector
Industry

Champions Oncology, Inc. Target price 2024 - Analyst rating & recommendation

Champions Oncology, Inc. Classifications & Recommendation:

Buy
100%

Champions Oncology, Inc. Price Target

Target Price $6.00
Price $4.50
Potential
Number of Estimates 1
1 Analyst has issued a Champions Oncology, Inc. price target 2025. The average Champions Oncology, Inc. target price is $6.00. This is higher than the current stock price.
A rating was issued by 1 analysts: 1 Analysts recommend Champions Oncology, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Champions Oncology, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Champions Oncology, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Apr '24 2025
Estimates
Revenue Million $ 50.16 53.73
6.89% 7.11%
EBITDA Margin -10.07% 6.76%
333.88% 167.14%

1 Analyst has issued a sales forecast Champions Oncology, Inc. 2025 . The average Champions Oncology, Inc. sales estimate is

$53.7m
Unlock
. This is
4.02% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$53.7m 4.02%
Unlock
, the lowest is
$53.7m 4.02%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $50.2m 6.89%
2025
$53.7m 7.11%
Unlock
2026
$59.0m 9.76%
Unlock

1 Analyst has issued an EBITDA forecast Champions Oncology, Inc. 2025 . The average Champions Oncology, Inc. EBITDA estimate is

$3.6m
Unlock
. This is
512.50% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$3.6m 512.50%
Unlock
, the lowest is
$3.6m 512.50%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-5.1m 304.00%
2025
$3.6m 171.88%
Unlock
2026
$4.6m 25.67%
Unlock

EBITDA Margin

2024 -10.07% 333.88%
2025
6.76% 167.14%
Unlock
2026
7.74% 14.50%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Apr '24 2025
Estimates
EV/Sales 1.22

Based on analysts' sales estimates for 2025, the Champions Oncology, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.27 14.77%
2025
1.22 3.69%
Unlock
2026
1.11 8.89%
Unlock

P/S ratio

Current 1.18 17.03%
2025
1.14 3.87%
Unlock
2026
1.04 8.89%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today